Jain Sunil K, Agrawal Govind P, Jain Narendra K
SLT Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, India.
Drug Dev Ind Pharm. 2007 Apr;33(4):381-91. doi: 10.1080/03639040600920655.
A floating granular delivery system consisting of calcium silicate (CS) as porous carrier; repaglinide (Rg), an oral hypoglycemic agent; and hydroxypropyl methylcellulose K4M (HPMC K4M), ethyl cellulose (EC) and carbopol 940 (CP940) as matrix forming polymers was prepared and evaluated for its gastro-retentive and controlled release properties. The effect of various formulation and process variables on the particle morphology, micromeritic properties, in vitro floating behavior, drug content (%) and in vitro drug release was studied. The transit of floating granules of optimized formulation in the gastrointestinal (GI) tract was monitored by gamma scintigraphy in albino rabbits. The optimized formulation was compared in vivo with lactose granules (RgSCLG) prepared from identical polymers with their optimized composition ratio. Repaglinide-loaded optimized formulation was orally administered to albino rabbits and blood samples collected were used to determine pharmacokinetic parameters of Rg from floating granular formulation. Results were compared with pharmacokinetic parameters of marketed tablet formulation of Rg. The optimized formulation (RgSCG4) demonstrated favorable in vitro floating and release characteristics. Prolonged gastric residence time (GRT) of over 6 hr was achieved in all subjects for calcium silicate based floating granules of Rg. The relative bioavailability of Rg-loaded floating granules increased 3.8-fold in comparison to that of its marketed capsule. The designed system, combining excellent buoyant ability and suitable drug release pattern, offered clear advantages in terms of increased bioavailability of repaglinide.
制备了一种漂浮颗粒给药系统,其由硅酸钙(CS)作为多孔载体、瑞格列奈(Rg)(一种口服降糖药)以及羟丙基甲基纤维素K4M(HPMC K4M)、乙基纤维素(EC)和卡波姆940(CP940)作为成膜聚合物组成,并对其胃滞留和控释性能进行了评价。研究了各种制剂和工艺变量对颗粒形态、粉体学性质、体外漂浮行为、药物含量(%)和体外药物释放的影响。通过γ闪烁显像法监测白化兔胃肠道中优化制剂的漂浮颗粒的转运情况。将优化制剂与由相同聚合物按其优化组成比例制备的乳糖颗粒(RgSCLG)进行体内比较。将载有瑞格列奈的优化制剂口服给予白化兔,并采集血样用于测定漂浮颗粒制剂中Rg的药代动力学参数。将结果与Rg市售片剂制剂的药代动力学参数进行比较。优化制剂(RgSCG4)表现出良好的体外漂浮和释放特性。对于基于硅酸钙的Rg漂浮颗粒,所有受试者的胃滞留时间(GRT)均延长至6小时以上。载有Rg的漂浮颗粒的相对生物利用度与其市售胶囊相比提高了3.8倍。所设计的系统结合了优异的漂浮能力和合适的药物释放模式,在提高瑞格列奈生物利用度方面具有明显优势。